Tebipenem HBr | DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

GSK Tebipenem NDA Resubmission

March 28, 2026 Evan Vega

GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data

GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.